论文部分内容阅读
目的：观察噻氯匹定治疗急性脑梗死后临床体征及各项实验检查指标的变化。方法：治疗组口服噻氯匹定250mg／d，共21天；对照组口服肠溶阿司匹林100mg／d，共21天。其余治疗两组相同。分别对患者治疗前和治疗后第7，14，21天神经功能缺损进行评分，作血液流变学各项目检查。结果：治疗组治疗后神经功能缺损评分明显低于对照组（P＜0．05），显效率和总有效率亦明显高于对照组（P＜0．05），两组治疗后血小板聚集率和出血时间均有显著变化，但治疗组更为显著，全血粘度、白细胞计数也明显下降（P＜0.05），对照组则无明显变化。结论：噻氯匹定治疗脑梗死优于肠溶阿司匹林，是预防和治疗缺血性脑血管病的理想药物。
OBJECTIVE: To observe the changes of clinical signs and indexes of various tests after ticlopidine treatment of acute cerebral infarction. Methods: The treatment group was given ticlopidine 250mg / d for 21 days. The control group was given aspirin 100mg / d orally for 21 days. The rest of the treatment two groups the same. Patients were treated before and after treatment on the 7th, 14th and 21st day neurological deficit score for each item of blood rheology examination. Results: After treatment, the score of neurological deficit in the treatment group was significantly lower than that in the control group (P <0.05), and the effective rate and total effective rate were significantly higher in the treatment group than those in the control group (P <0.05). The platelet aggregation rate And bleeding time had significant changes, but the treatment group was more significant, whole blood viscosity, white blood cell count also significantly decreased (P <0.05), the control group had no significant change. Conclusion: Ticlopidine is superior to enteric-coated aspirin in the treatment of cerebral infarction and is an ideal medicine for the prevention and treatment of ischemic cerebrovascular disease.